Docetaxel

Advance Directives, Advance Directives, Metastatic Hormone-Refractory Prostate Cancer + 13 more
Treatment
20 FDA approvals
20 Active Studies for Docetaxel

What is Docetaxel

DocetaxelThe Generic name of this drug
Treatment SummaryDocetaxel is a chemotherapy drug used to treat certain types of cancer, such as breast, ovarian, and non-small cell lung cancer. It works by blocking the growth of cancer cells by binding to a protein in them called tubulin.
Taxotereis the brand name
image of different drug pills on a surface
Docetaxel Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Taxotere
Docetaxel
2008
97

Approved as Treatment by the FDA

Docetaxel, also known as Taxotere, is approved by the FDA for 20 uses such as Carcinoma, Non-Small-Cell Lung and Non-Small Cell Lung Carcinoma .
Carcinoma, Non-Small-Cell Lung
Used to treat metastatic untreated non small cell lung cancer in combination with Cisplatin
Non-Small Cell Lung Carcinoma
Neoplasm Metastasis
Metastatic Hormone-Refractory Prostate Cancer
Used to treat refractory, metastatic hormone-refractory Prostate cancer in combination with Prednisone
Metastatic Breast Cancer
Node Positive Breast Cancer
Used to treat Node Positive Breast Cancer in combination with Cyclophosphamide
Advance Directives
Ovarian Cancer Metastatic
Advance Directives
Used to treat advanced untreated gastric adenocarcinoma in combination with Cisplatin
metastatic untreated non small cell lung cancer
Used to treat metastatic untreated non small cell lung cancer in combination with Cisplatin
refractory, metastatic hormone-refractory Prostate cancer
Used to treat refractory, metastatic hormone-refractory Prostate cancer in combination with Prednisone
locally advanced untreated non small cell lung cancer
Used to treat locally advanced untreated non small cell lung cancer in combination with Cisplatin
refractory, metastatic Non small cell lung cancer
Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Metastatic Breast Cancer
Squamous Cell Carcinoma of Head and Neck
BRCA1 gene
Malignant Neoplasms
Used to treat Node Positive Breast Cancer in combination with Cyclophosphamide
Advance Directives
Used to treat locally advanced Squamous cell carcinoma of head and neck in combination with Cisplatin
Advance Directives
Used to treat locally advanced untreated non small cell lung cancer in combination with Cisplatin

Effectiveness

How Docetaxel Affects PatientsDocetaxel is a cancer-fighting drug that helps stop cancer cells from growing. It works by forming a stable network of microtubules in the cells, which stops them from reorganizing and performing their normal functions. Docetaxel also causes abnormal clusters of microtubules to form during cell division, which further restricts the cancer cells' growth.
How Docetaxel works in the bodyDocetaxel stops cells from functioning properly by making the part of the cell that helps it move, called microtubules, stay in one place. Docetaxel binds to the parts of the microtubules called tubulin, making them unable to shorten or lengthen. This makes it difficult for the cell to move things around, like chromosomes during mitosis. Additionally, docetaxel can make cancer cells die by binding to a protein that stops apoptosis, called Bcl-2.

When to interrupt dosage

The advised dose of Docetaxel depends upon the diagnosed condition, including Esophageal Cancer, Neoplasm Metastasis and Non-Small Cell Lung Carcinoma. The quantity of dosage fluctuates, depending on the approach of administration (e.g. Intravenous or Injection, solution, concentrate - Intravenous) as mentioned in the table below.
Condition
Dosage
Administration
Metastatic Hormone-Refractory Prostate Cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Malignant Neoplasms
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Small Cell Lung Cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Urinary Bladder Neoplasms
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Soft Tissue Sarcoma
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Neoplasm Metastasis
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Squamous Cell Carcinoma of Head and Neck
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Non-Small Cell Lung Carcinoma
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Sarcoma
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
BRCA1 gene
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Advance Directives
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Metastatic Breast Cancer
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous
Carcinoma, Non-Small-Cell Lung
20.0 mg/mL, 80.0 mg/mL, , 10.0 mg/mL, 80.0 mg, 20.0 mg, 160.0 mg/mL, 180.0 mg/mL, 120.0 mg/mL, 200.0 mg/mL, 140.0 mg/mL, 40.0 mg/mL, 16.0 mg/mL
Intravenous, , Injection, solution, concentrate - Intravenous, Injection, solution, concentrate, Injection, solution, Injection, solution - Intravenous, Kit, Injection, Injection - Intravenous, Solution, Solution - Intravenous, Kit; Solution, Kit; Solution - Intravenous

Warnings

Docetaxel Contraindications
Condition
Risk Level
Notes
neutrophil count <1500 cells/mm3
Do Not Combine
There are 20 known major drug interactions with Docetaxel.
Common Docetaxel Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Docetaxel.
Abetimus
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with Abetimus.
Acteoside
Major
The risk or severity of adverse effects can be increased when Docetaxel is combined with Acteoside.
Docetaxel Toxicity & Overdose RiskThe lowest toxic dose of this drug in rats is greater than 2000 mg/kg. Symptoms of overdose can include a decrease in the number of white blood cells, nerve damage, and inflammation of the lining of the digestive tract. In two cases of overdose, one patient received 150 mg/m2 and the other received 200 mg/m2 as 1-hour infusions. Both suffered from low white blood cell count, weakness, skin reactions, and pins and needles sensations. Thankfully they both recovered without any long-term effects.
image of a doctor in a lab doing drug, clinical research

Docetaxel Novel Uses: Which Conditions Have a Clinical Trial Featuring Docetaxel?

Currently, 378 active studies are evaluating the potential of Docetaxel to treat metastatic untreated non-small cell lung cancer, Sarcoma and Advance Directives.
Condition
Clinical Trials
Trial Phases
Metastatic Breast Cancer
1 Actively Recruiting
Phase 1, Phase 2
Metastatic Hormone-Refractory Prostate Cancer
80 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 4, Phase 3, Early Phase 1
BRCA1 gene
15 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1
Non-Small Cell Lung Carcinoma
0 Actively Recruiting
Advance Directives
0 Actively Recruiting
Small Cell Lung Cancer
45 Actively Recruiting
Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1
Advance Directives
0 Actively Recruiting
Carcinoma, Non-Small-Cell Lung
0 Actively Recruiting
Neoplasm Metastasis
1 Actively Recruiting
Phase 2
Soft Tissue Sarcoma
58 Actively Recruiting
Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1
Advance Directives
0 Actively Recruiting
Squamous Cell Carcinoma of Head and Neck
10 Actively Recruiting
Phase 1, Phase 2, Phase 3
Sarcoma
1 Actively Recruiting
Phase 2
Advance Directives
0 Actively Recruiting
Malignant Neoplasms
4 Actively Recruiting
Not Applicable, Phase 2
Urinary Bladder Neoplasms
0 Actively Recruiting

Docetaxel Reviews: What are patients saying about Docetaxel?

5Patient Review
3/20/2010
Docetaxel for Non-Small Cell Lung Cancer
Today was my first time using this treatment, and I thought it was great!
4.3Patient Review
8/7/2009
Docetaxel for Non-Small Cell Lung Cancer
So far, this has been working well for me with no noticeable side effects like nausea or vomiting. I'm on my third treatment--taking it once a week--and also doing radiation therapy five days a week.
4Patient Review
9/12/2012
Docetaxel for Breast Cancer that has Spread to Another Part of the Body
This treatment was successful in reducing the size of my tumors and the amount of pleural fluid in my lungs. I now have an improved quality of life and breath much better than before.
4Patient Review
11/29/2012
Docetaxel for Cancer of Prostate that has Spread to Other Part of Body
Taxatere was successful for me for three years, but my PSA levels began to rise again. I am now on docetaxel and this is my third treatment. I am hoping and praying that this will be successful for another three years.
2.7Patient Review
1/21/2010
Docetaxel for Cancer of Prostate that has Spread to Other Part of Body
I've been taking this medication for 25 months, and I'm starting to see serious adverse effects. These include issues with my taste buds, fatigue, skin bruising, and nails as well as recurrent cancer growth. I don't think the benefits are worth the risks anymore.
View All Reviews
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about docetaxel

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the most common side effect of docetaxel?

"The two most common long-term side effects of docetaxel chemotherapy are sensory and motor peripheral neuropathy, which are fortunately much less common than with paclitaxel. Grade 3 and 4 neuropathy is only observed in less than 10% of patients receiving docetaxel therapy."

Answered by AI

What is the docetaxel used for?

"Docetaxel injection is used to treat patients with advanced or metastatic breast cancer who have previously received other cancer medicines that were ineffective."

Answered by AI

What is the success rate of docetaxel?

"Docetaxel combined with another antineoplastic resulted in a 20-54% objective response rate for chemotherapy-naive patients. Triple chemotherapy combinations resulted in a 51-60% response rate for patients."

Answered by AI

Is docetaxel a strong chemotherapy?

"Since docetaxel is a potent chemotherapeutic agent, it produces numerous side effects. The most common ones are nausea, vomiting, and hair loss."

Answered by AI

Clinical Trials for Docetaxel

Have you considered Docetaxel clinical trials? We made a collection of clinical trials featuring Docetaxel, we think they might fit your search criteria.
Have you considered Docetaxel clinical trials? We made a collection of clinical trials featuring Docetaxel, we think they might fit your search criteria.
Have you considered Docetaxel clinical trials? We made a collection of clinical trials featuring Docetaxel, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top